Prospective Data Collection Initiative on Thoracic Malignancies

Launched by DUTCH SOCIETY OF PHYSICIANS FOR PULMONOLOGY AND TUBERCULOSIS · May 28, 2025

Keywords

ClinConnect Summary

This clinical trial, called the Prospective Data Collection Initiative on Thoracic Malignancies, aims to better understand how various factors influence the outcomes of patients with thoracic cancers like lung cancer and mesothelioma. Researchers are interested in not just the stage of the cancer but also other things like genetic information, treatment responses, and personal health history. By studying a broader group of patients who are typically not included in clinical trials, the researchers hope to gather valuable data that can help improve treatments and outcomes for everyone affected by these cancers.

To participate in this study, individuals must be at least 18 years old and have a confirmed or highly suspected diagnosis of a thoracic cancer. They will need to give their consent to share information over time as part of the study. While the trial is not yet recruiting participants, those who join can expect to contribute to important research that could lead to better care for future patients with similar conditions. It’s important to note that individuals who are unable to provide informed consent due to mental challenges will not be eligible for this study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 years;
• • Histo/cytopathological proof of a thoracic malignancy, or a strong suspicion (after imaging and multidisciplinary board);
• • Informed consent for longitudinal observational data collection;
• Exclusion Criteria:
• • Mentally challenged patients that are unable to provide conscientious informed consent as determined by the investigator.
• • Inability to provide a written or electronic informed consent.